Q53. During the review of a design dossier, the reviewer asks why the company has only carried out a top-down risk approach. The reviewer is referring to which of the following?

Q54. According to ICH, what is the MAXIMUM amount of time in calendar days that an organization has from the initial receipt of information to report serious and unexpected ADR of a marketed product to regulatory authorities?

Q55. A regulatory authority announces an inspection of a regulatory affairs professional’s facility during a holiday season when most of the staff Is not available. What is the MOST practical approach to this dilemma?

Q56. Which of the following is the BEST approach for mitigating potential regulatory compliance issues at your company?

Q57. A regulatory affairs professional is asked to review and update regulatory affairs SOPs.
Which aspect of the SOP Is MOST important to consider?

Q58. Which of the following statements regarding export regulations for an approved product is CORRECT?

Q59. A process is ultimately validated to ensure which of the following?

Q60. A company establishes a new medical device indication for its consumer disposable products. The regulatory affairs professional is asked to give a 30-minute training session on these products to sales representatives. Which of the following subjects is the MOST important to discuss?

Q61. Which of the following claims would classify an apple as a drug?

Q62. At the last internal audit, a regulatory affairs professional identified a need for a corrective action for the manufacturing process. Which of the following stakeholders should be notified FIRST?

Q63. During face-to-face meetings with the regulatory authority to address submission issues, what is the BEST choice for the number of company representatives who should attend?

Q64. A company is developing a new medical device.
During which initial stage is it MOST appropriate (or a regulatory affairs professional to become involved?

Q65. A clinical study of a drug is completed to support a marketing approval application.
According to ICH, how long should a sponsor retain the clinical study essential documents?

Q66. As part of the regulatory strategy for companies intending to manufacture a psychotropic product, which of the following approvals should be received FIRST?

Q67. A company is developing a device-drug combination product. Which of the following should be evaluated FIRST in order to determine the applicable guidance documents?